Revenue Jumps 17%, Gross Profit Up 68% for 20/20 BioLabs in FY25
AIDX sits 26% above its 52-week low of $1.51 on light trading volume (0.1× avg).
Summary
20/20 BioLabs reported strong full-year 2025 financial results, with revenue increasing 17% to $2.0 million and gross profit surging 68% to $0.6 million, expanding gross margin by 900 basis points. The company also significantly improved its net loss by 33% to ($3.7) million and reduced cash used in operating activities. This positive financial trajectory is further bolstered by a recently completed $5.0 million private placement, providing crucial capital for the micro-cap company. The report also highlighted recent operational progress, including the previously announced $520,000 in Maryland state funding for cancer screenings and an exclusive U.S. license agreement with ROKIT Healthcare, which are expected to drive future revenue growth. These developments, coupled with its recent Nasdaq listing, position 20/20 BioLabs for substantial expansion in 2026, making this a material update for investors.
At the time of this announcement, AIDX was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $1.51 to $50.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.